EFFECTIVENESS OF RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD): REAL WORLD OUTCOMES FROM THE SECOND INTERIM ANALYSIS OF THE LUMINOUS STUDY

被引：0
|
作者：
Gilhotra, Jagjit Singh [1 ,2 ]
Mitchell, Paul [3 ]
Vote, Brendan [4 ]
Lacey, Sue
机构：
[1] Univ Adelaide, Dept Ophthalmol, Adelaide, SA, Australia
[2] Queen Elizabeth Hosp, Dept Ophthalmol, Adelaide, SA, Australia
[3] Univ Sydney, Dept Ophthalmol & Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia
[4] Launceston Eye Inst, Launceston, Tas, Australia
[5] Novartis Pharma AG, Basel, Switzerland
来源：
CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | 2015年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
110
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [21] Ranibizumab for neovascular age-related macular degeneration
    Gillies, Mark C.
    Wong, Tien Y.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (07): : 748 - 749
  • [22] Ranibizumab in neovascular age-related macular degeneration
    Eng, Kenneth T.
    Kertes, Peter J.
    [J]. CLINICAL INTERVENTIONS IN AGING, 2006, 1 (04) : 451 - 466
  • [23] Short-Term Outcomes of Eyes with Neovascular Age-related Macular Degeneration (nAMD) that Switched from Aflibercept to Ranibizumab
    Hsu, Jason
    Obeid, Anthony
    Mellen, Phoebe L.
    Wibbelsman, Turner D.
    Konkoly, Michelle A.
    Velez, Michael R.
    Calem, Daniel B.
    Sioufi, Kareem
    Su, Daniel
    Storey, Philip
    Klufas, Michael A.
    Spirn, Marc J.
    Regillo, Carl
    Ho, Allen C.
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [24] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Chang, Yi-Sheng
    Lee, Wan-Ju
    Lim, Chen-Chee
    Wang, Shih-Hao
    Hsu, Sheng-Min
    Chen, Yi-Chian
    Cheng, Chia-Yi
    Teng, Yu-Ti
    Huang, Yi-Hsun
    Lai, Chun-Chieh
    Tseng, Sung-Huei
    [J]. SCIENTIFIC REPORTS, 2018, 8
  • [25] Treatment of neovascular age-related macular degeneration with Ranibizumab/LucentisTM
    Michels, S
    Rosenfeld, PJ
    [J]. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2005, 222 (06) : 480 - 484
  • [26] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Yi-Sheng Chang
    Wan-Ju Lee
    Chen-Chee Lim
    Shih-Hao Wang
    Sheng-Min Hsu
    Yi-Chian Chen
    Chia-Yi Cheng
    Yu-Ti Teng
    Yi-Hsun Huang
    Chun-Chieh Lai
    Sung-Huei Tseng
    [J]. Scientific Reports, 8
  • [27] Ranibizumab for the treatment of neovascular age-related macular degeneration: A review
    Kourlas, Helen
    Abrams, Paris
    [J]. CLINICAL THERAPEUTICS, 2007, 29 (09) : 1850 - 1861
  • [28] Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
    Martin, Daniel F.
    Maguire, Maureen G.
    Fine, Stuart L.
    Ying, Gui-shuang
    Jaffe, Glenn J.
    Grunwald, Juan E.
    Toth, Cynthia
    Redford, Maryann
    Ferris, Frederick L., III
    [J]. OPHTHALMOLOGY, 2012, 119 (07) : 1388 - 1398
  • [29] Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands
    Verbraak, Frank D.
    Ponsioen, Dirk L.
    Tigchelaar-Besling, Odette A. M.
    Nguyen, Vuong
    Gillies, Mark C.
    Barthelmes, Daniel
    Klaver, Caroline C. W.
    [J]. ACTA OPHTHALMOLOGICA, 2021, 99 (06) : E884 - E892
  • [30] Ranibizumab: treatment in patients with neovascular age-related macular degeneration
    Pieramici, Dante J.
    Avery, Robert L.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2006, 6 (11) : 1237 - 1245
12345